Ph.D., COO, ATOM Consortium
Stacie Calad-Thomson is Chief Operating Officer of the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium, a new public-private partnership that aims to accelerate the discovery of effective cancer therapies through integration of high-performance computing, diverse biological data, and emerging biotechnologies. Founding consortium members include the Department of Energy’s Lawrence Livermore National Laboratory, GSK, the National Cancer Institute’s Frederick National Laboratory for Cancer Research, and the University of California, San Francisco. The goal of the consortium is to create a new paradigm of drug discovery that would reduce the time from an identified drug target to clinical candidate from the current approximately six years to just 12 months. Stacie has worked for GSK, starting as a chemist and moving into business strategy and operations roles within R&D Platform Technology & Sciences, where she led several change initiatives. She has a BS (UC Berkeley) and a PhD (UC Irvine) in chemistry.
Session Abstract – PMWC 2018 Silicon Valley
Session Synopsis: The scope of precision medicine demands expertise and resources represented in multiple sectors and agencies, and therefore new types of partnerships. Representatives from industry, academia and federal agencies will consider the challenges and opportunities of such collaborations in this panel, drawing on two specific demonstration cases, both of which require high performance computing: the ATOM Program, a revolutionary approach to cancer drug discovery; and the VA Million Veterans Program, utilizing patient medical records to enhance health research.